Leucid is progressing novel cart therapies that produce a better and more durable response.
Business Model: Non-Profit
Revenue: $0
Employees: 11-50
Address: 3rd Floor, Bermondsey Wing
City: London
State: england
Zip: SE1 9RT
Country: GB
Leucid Bio is a pioneering biotech company developing cell therapies for refractory cancers, especially solid tumors. Leucid was founded to translate 20 years of King&s;s College London (King&s;s) research in the CAR-T field and is led by a highly experienced management team with both scientific and commercial expertise. As part of Leucid&s;s ongoing relationship with King&s;s, it benefits from exclusive access to and resources from the deep scientific, clinical, and manufacturing expertise of Dr. Maher and his academic team of immuno-oncology experts.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 10/2021 | Series A | $15.9M |
Epidarex Vulpes Investment Management 2Invest Future Fund of the British Business Bank Sofinnova Partners |
10/2021 | Series A | 5 | $15.9M |
2invest British Business Bank Epidarex Capital Sofinnova Partners Vulpes Investment Management Pte Ltd 2invest British Business Bank Epidarex Capital Sofinnova Partners Vulpes Investment Management Pte Ltd |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|